Our Pipeline

Targovax has differentiated assets with orphan indications

Phase 1
Phase 2
Phase 3
Pancreatic Cancer*
Colorectal Cancer
Ovarian and Colorectal Cancer*
Prostate Cancer

A broad and diversified pipeline in multiple indications
Low price tag on go/no-go decisions
*Orphan Drug Designations (ODD)

Targovax is an innovation driven specialist in immuno-oncology.

Targovax is a clinical stage immuno-oncology company dedicated to the development of highly targeted immunotherapy treatments for cancer patients.
Targovax is developing two complementary and highly targeted approaches to cancer immunotherapy:

  • the TG platform are neo-antigen cancer vaccines designed to specifically treat tumors that express mutated forms of RAS
  • the ONCOS-102 platform, a virus-based oncolytic immunotherapy based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumor

Both treatment approaches harness the patient’s own immune system to fight the cancer.

Targovax is committed to the design and development of highly targeted immunotherapy for patients with RAS-mutated cancers – an area of high unmet medical need with few and limited treatment options – and for patients with difficult to treat solid tumors.

The Targovax pipeline, built on a robust knowledge of the immunotherapy area and unique technologies, includes a number of product candidates targeted at a wide range of cancer types. Its lead candidates, TG01 and ONCOS-102 have successfully completed Phase I clinical trials and are currently being tested in further early-stage clinical trials (Phase I and/or Phase II)

RAS mutations and cancer

One of Targovax's therapeutic approaches is a neo-antigen immunotherapy targeting mutations in the RAS genes associated with cancer. Mutation of RAS disrupts normal cell division signalling, and occurs early in the transformation from a normal to a cancer cell.

RAS mutations are a key driver of cancer progression and treatment resistance. They are found in 20 - 30% of all cancers1, over 90% of pancreatic cancers2, 50% of colorectal cancers3, between 20 and 30% of non-small cell lung cancers4 and between 20 and 30% of malignant melanomas1.

Few treatment options are available for patients with RAS mutations and of limited efficacy, highlighting the significant unmet medical need for these patients.

Adenoviruses and Cancer

Targovax is also developing a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.

This cancer immunotherapeutic technology has a targeted mechanism of action making tumors visible to the immune system and educating the immune system to recognize and attack patient specific tumor cells. The technology is based on adenoviruses engineered to kill tumor cells primarily via activation of a systemic, patient-targeted anti-tumor immune response.

IPR / Market protection

Targovax owns a patent portfolio protecting its pipeline with patents and patent applications from different patent families covering its products, expiring from 2029 to 2035.

Orphan Drug Designation (ODD) has been granted in the EU and the US for TG01 for pancreatic cancer, and for ONCOS-102 for the indications of mesothelioma, soft tissue sarcoma and ovarian cancer.

ODD ensures 10 and 7 years of market protection in the EU and in the US, respectively, from the date of market approval.


  1. Fernandez-Medarde, A. and Santos, E.; RAS in Cancer and Developmental Diseases; Genes & Cancer. 2011;2(3):344–358
  2. Raphael B.J. et al; Integrated genomic characterization of pancreatic ductal adenocarcinoma; Cancer Cell 32, 185-203, August 14, 2017
  3. Van Cutsem, E. et al; Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer; J Clin Oncol. 2015; 33(7):692-700
  4. D’Arcangelo, M. and Cappuzzo, F.; K-RAS Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value; International Scholarly Research Network, ISRN Molecular Biology, Volume 2012, Article ID 837306, 8p.